Literature DB >> 6776015

Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy.

G Cuilleret, G Pomier-Layrargues, F Pons, J Cadilhac, H Michel.   

Abstract

Hepatic encephalopathy (HE) is currently felt to be secondary to a disturbance in the metabolism of cerebral catecholamines with a decline in dopamine and noradrenaline and a rise in the false neurotransmitter octopamine. The aim of this study was to evaluate brain tissue levels of dopamine, noradrenaline, and octopamine in patients with cirrhosis and HE. This study includes 34 patients: 22 were cirrhotic, 12 were control subjects. Among the 22 cirrhotic patients, 19 had HE, three did not. Tissue specimens were obtained at necropsy from the locus niger, caudate nucleus, hypothalamus, thalamus and frontal cortex, and from the frontal cortex during neurosurgical procedures. Our results showed that (1) dopamine and noradrenaline levels are identical in cirrhotic patients with or without HE and in patients without liver disease (P < 0.05); (2) octopamine levels are higher in control subjects than in patients with cirrhosis and HE. In conclusion, there is no decline in dopamine and noradrenaline levels in the brain tissues of cirrhotic patients with HE, and this is in contradication with the animal findings; octopamine levels are not raised. Hepatic encephalopathy in human liver cirrhosis does not seem to be secondary to a disturbance in cerebral catecholamines.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776015      PMCID: PMC1419880          DOI: 10.1136/gut.21.7.565

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Stability of enzymes in post-mortem rat brain.

Authors:  S Fahn; L J Côté
Journal:  J Neurochem       Date:  1976-05       Impact factor: 5.372

2.  Cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid, lactic acid, and pH before and after probenecid in hepatic coma.

Authors:  S Lal; A Aronoff; E Garelis; T L Sourkes; S N Young; C E de la Vega
Journal:  Clin Neurol Neurosurg       Date:  1975-12       Impact factor: 1.876

3.  Reversible modifications of neurotransmitters of the brain in experimental acute hepatic coma.

Authors:  P Bloch; M L Delorme; J R Rapin; A Granger; M Boschat; P Opolon
Journal:  Surg Gynecol Obstet       Date:  1978-04

4.  Can hepatic coma be caused by a reduction of brain noradrenaline or dopamine?

Authors:  L Zieve; R L Olsen
Journal:  Gut       Date:  1977-09       Impact factor: 23.059

5.  Depletion of brain norepinephrine in acute hepatic coma.

Authors:  J M Dodsworth; J H James; M C Cummings; J F Fischer
Journal:  Surgery       Date:  1974-06       Impact factor: 3.982

Review 6.  Catecholamines.

Authors:  J Axelrod; R Weinshilboum
Journal:  N Engl J Med       Date:  1972-08-03       Impact factor: 91.245

7.  Post-mortal changes of dopamine and homovanillic acid levels in rat striatum as measured by mass fragmentography.

Authors:  F A Wiesel; G Sedvall
Journal:  Brain Res       Date:  1974-01-18       Impact factor: 3.252

8.  False neurotransmitters and hepatic failure.

Authors:  J E Fischer; R J Baldessarini
Journal:  Lancet       Date:  1971-07-10       Impact factor: 79.321

9.  An enzymatic assay for octopamine and other beta-hydroxylated phenylethylamines.

Authors:  P B Molinoff; L Landsberg; J Axelrod
Journal:  J Pharmacol Exp Ther       Date:  1969-12       Impact factor: 4.030

10.  Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia.

Authors:  A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

View more
  16 in total

Review 1.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

Review 2.  Interrelationships of liver and brain with special reference to Reye syndrome.

Authors:  J K Brown; H Imam
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Dopamine in the pathogenesis of minimal hepatic encephalopathy: a new player?

Authors:  Rahul Rai; Radha K Dhiman
Journal:  Hepatol Int       Date:  2013-09-10       Impact factor: 6.047

Review 4.  Branched chain amino acids in liver disease: fact or fantasy?

Authors:  D B Silk
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

5.  Brain tyrosine hydroxylase activity and calculated amount of brain dopa synthesized in carbon tetrachloride-intoxicated rats.

Authors:  N Takei; A Watanabe; T Sakata; S Hayashi; T Obata; T Shiota; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1983-02

6.  The turnover of brain monoamines after total hepatectomy in rats infused with branched chain amino acids.

Authors:  M Bugge; F Bengtsson; A Nobin; B Jeppsson; P Herlin
Journal:  World J Surg       Date:  1987-12       Impact factor: 3.352

Review 7.  Progress in the treatment of chronic portasystemic encephalopathy.

Authors:  I R Crossley; R Williams
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

8.  Raised plasma concentrations of 3-methoxy-4-hydroxyphenylethyleneglycol in cirrhotic patients with or without hepatic encephalopathy.

Authors:  H Echizen; A Minegishi; S Hayashi; N Umeda; T Oda; T Ishizaki
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

9.  Hypothalamic-pituitary dopaminergic function in hepatic failure in man.

Authors:  S Lal; M Oravec; A Aronoff; M E Kiely; H Guyda; S Solomon; N P Nair
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

10.  Blood and brain concentrations of mercaptans in hepatic and methanethiol induced coma.

Authors:  H Al Mardini; K Bartlett; C O Record
Journal:  Gut       Date:  1984-03       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.